Centers | ||
|
|
|
Drug Discovery Core | EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) |
The Drug Discovery Core at the University of Utah is an established Service/Recharge center that provides compound collections for screening by University of Utah Faculty. Our mission is to provide customers low-cost and efficient access to chemical... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Partnerships |
Events |
Jobs |
GSK and Yale to partner on drug discovery developmentGlaxoSmithKline (GSK) and Yale University will partner to design a new class of molecules to target disease-causing proteins. This is the latest in a string of deals between Yale’s academic researchers and global pharmaceutical companies. View all Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all Sanofi and Weill Cornell Medical College to Discover New Drus to Treat TuberculosisSanofi has entered into a new collaboration with Dr.Carl Nathan's laboratory at Weill Cornell Medical College to screen existing compounds and develop new compounds to shorten the course of treatment of tuberculosis and increase effectiveness of... View all |
No EVENTS for listing |
No Job Posts |
